Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Article

Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling

Elisa Landoni, Giovanni Fucá, Jian Wang, Venkat R Chirasani, Zhiyuan Yao, Elena Dukhovlinova, Soldano Ferrone, Barbara Savoldo, Lee Kyung Hong, Peishun Shou, Silvia Musio, Francesco Padelli, Gaetano Finocchiaro, Miriam Droste, Brian Kuhlman, Abdijapar Shamshiev, Serena Pellegatta, Nikolay V. Dokholyan and Gianpietro Dotti
Elisa Landoni
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Fucá
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Wang
2Pharmacology, Pennsylvania State University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jian Wang
Venkat R Chirasani
3Department of Pharmacology, Pennsylvania State University College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiyuan Yao
4Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zhiyuan Yao
Elena Dukhovlinova
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soldano Ferrone
5Surgery, Harvard Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Soldano Ferrone
Barbara Savoldo
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee Kyung Hong
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peishun Shou
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peishun Shou
Silvia Musio
6Laboratory of Immunotherapy of Brain Tumors, Fondazione IRCCS Istituto Neurologico Carlo Besta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silvia Musio
Francesco Padelli
7Experimental Imaging and Neuro-Radiology, Fondazione IRCCS Istituto Neurologico Carlo Besta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francesco Padelli
Gaetano Finocchiaro
8Neuro-Oncology, Istituto Neurologico Besta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gaetano Finocchiaro
Miriam Droste
9Cell Medica Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Kuhlman
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdijapar Shamshiev
10R&D, Cell Medica Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serena Pellegatta
6Laboratory of Immunotherapy of Brain Tumors, Fondazione IRCCS Istituto Neurologico Carlo Besta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Serena Pellegatta
Nikolay V. Dokholyan
3Department of Pharmacology, Pennsylvania State University College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nikolay V. Dokholyan
Gianpietro Dotti
11Lineberger Comprehensive Cancer Center, University of North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gdotti@med.unc.edu
DOI: 10.1158/2326-6066.CIR-20-0451
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chimeric antigen receptor (CAR) tonic signaling, defined as spontaneous activation and release of proinflamatory cytokines by CAR-T cells, is considered a negative attribute because it leads to impaired antitumor effects. Here, we report that CAR tonic signaling is caused by the intrinsic instability of the monoclonal antibody single-chain variable fragment (scFv) to promote self-aggregation and signaling via the CD3ζ chain incorporated into the CAR construct. This phenomenon was detected in a CAR encoding either CD28 or 4-1BB costimulatory endodomains. Instability of the scFv was caused by specific amino acids within the framework regions (FWRs) that can be identified by computational modeling. Substitutions of the amino acids causing instability, or humanization of the FWRs, corrected tonic signaling of the CAR, without modifying antigen specificity, and enhanced the antitumor effects of CAR-T cells. Overall, we demonstrated that tonic signaling of CAR-T cells is determined by the molecular instability of the scFv and that computational analyses of the scFv can be implemented to correct the scFv instability in CAR-T cells with either CD28 or 4-1BB costimulation.

  • Received May 29, 2020.
  • Revision received November 19, 2020.
  • Accepted February 2, 2021.
  • Copyright ©2021, American Association for Cancer Research.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

This OnlineFirst version was published on February 5, 2021
doi: 10.1158/2326-6066.CIR-20-0451

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling
Elisa Landoni, Giovanni Fucá, Jian Wang, Venkat R Chirasani, Zhiyuan Yao, Elena Dukhovlinova, Soldano Ferrone, Barbara Savoldo, Lee Kyung Hong, Peishun Shou, Silvia Musio, Francesco Padelli, Gaetano Finocchiaro, Miriam Droste, Brian Kuhlman, Abdijapar Shamshiev, Serena Pellegatta, Nikolay V. Dokholyan and Gianpietro Dotti
Cancer Immunol Res February 5 2021 DOI: 10.1158/2326-6066.CIR-20-0451

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling
Elisa Landoni, Giovanni Fucá, Jian Wang, Venkat R Chirasani, Zhiyuan Yao, Elena Dukhovlinova, Soldano Ferrone, Barbara Savoldo, Lee Kyung Hong, Peishun Shou, Silvia Musio, Francesco Padelli, Gaetano Finocchiaro, Miriam Droste, Brian Kuhlman, Abdijapar Shamshiev, Serena Pellegatta, Nikolay V. Dokholyan and Gianpietro Dotti
Cancer Immunol Res February 5 2021 DOI: 10.1158/2326-6066.CIR-20-0451
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Longitudinal Immune Profiling During Cancer Immunoediting
  • Boosting Eomes expression augments anti-tumor immunity
  • IDO1-dependent vascularizing cells at the IFNγ/IL6 interface
Show more Research Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement